Kevin Gorman, Neurocrine CEO

Bounc­ing back from a PhII flop in schiz­o­phre­nia, Neu­ro­crine steers in­to the busy M4/M1 path­way with a $100M cash deal

Eight months af­ter Neu­ro­crine $NBIX chron­i­cled a flop for a mid-stage schiz­o­phre­nia drug, the biotech is head­ed right back in­to Phase II armed with a new drug can­di­date from So­sei Hep­tares.

Neu­ro­crine out­lined a deal that pro­vides So­sei Hep­tares $100 mil­lion up­front, R&D ex­pens­es and a moth­er­lode of mile­stones worth up to $2.6 bil­lion if suc­cess­ful. That start­ing fig­ure close­ly re­sem­bles what the biotech paid Take­da to land 3 pro­grams, in­clud­ing the schiz­o­phre­nia drug TAK-831, which failed to mea­sure up in the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.